Your Yourlocation: Home > New tiotropium bromide(136310-93-5) preparations will soon be approved for the treatment of COPD

Spiriva Respimat was approved for the same treatment as a single dose of tiotropium bromide(136310-93-5) dry powder Spiriva HandiHaler, which was approved by the FDA in 2004 by inserting the capsules into the breath-activated HandiHaler device at each dose.

Boehringer Ingelheim said the Respimat device dose of 5μg, HandiHaler device dose of 18μg, both the pharmacokinetics and systemic exposure are similar. The panel agreed that there was no data to suggest that treatment with the Respimat device was more effective than using the HandiHaler, and that there was no data in the study indicating a better patient compliance with the Respimat device.

TIOSPIR was a randomized, double-blind, parallel-group study of more than 17,000 patients with COPD who were followed up for at least 2 years to investigate tiotropium bromide(136310-93-5) 5 μg 1 time /d and Respimat 2.5 μg 1 time /day in all-cause mortality was not inferior to that of tiotropium bromide(136310-93-5) 18 μg /d. All-cause mortality was similar in all three groups. The incidence of fatal MACE (major adverse cardiovascular events) was similar in the three groups, but there was a slight numerical difference between the two lethal MACE components (cardiac and fatal myocardial infarction).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved